NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: SOTAC · data 2026-11-01
Sotac Pharmaceuticals Limited
In plain words
Price: 20.1% below its 52-week high of ₹139.65.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹97 cr |
| Net profit (last 12 months) | ₹6 cr |
| Sales growth, 3 years (yearly) | 9.3% |
| Profit growth, 3 years (yearly) | 26.1% |
At a glance
P/E 21.4, P/B 2.1, dividend yield 0.2%. Price relative to earnings and book value (low is cheaper, not better).
ROE 10.3%, ROCE 17.4%, operating margin 8.6%: how much profit it earns on the money it uses.
Debt/equity 0.64, Profit growth 26.1% and sales growth 9.3% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 26.1% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Sotac Pharmaceuticals Limited debt-free?
Its latest reported debt-to-equity ratio is 0.64.
What is Sotac Pharmaceuticals Limited's P/E ratio?
About 21.4, based on the last 12 months' earnings and a price of ₹111.65 (data 2026-11-01).
What is the 52-week high and low of Sotac Pharmaceuticals Limited?
The 52-week high is ₹139.65 and the 52-week low is ₹86.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Sotac Pharmaceuticals Limited | ₹111.65 | ₹123 cr | 21.4 | 2.1 | 10.3% | 17.4% | 0.64 | -6.1% |
| Quest Laboratories Ltd. | ₹82 | ₹134 cr | 9 | 1.4 | 16.7% | 19.3% | 0.08 | -6.8% |
| Bal Pharma Limited | ₹81.85 | ₹129 cr | 18.1 | — | 7.9% | 19.2% | 2.03 | -2.4% |
| Krebs Biochemicals & Industries Ltd. | ₹56.6 | ₹126 cr | — | — | — | -17.3% | — | -18.6% |
| Parnax Lab Limited | ₹109.5 | ₹122 cr | 14.1 | — | 13.2% | 18% | 0.87 | +1.4% |
| Makers Laboratories Ltd | ₹200.9 | ₹119 cr | 34.7 | — | 3.3% | 7.3% | 0.08 | +22.1% |
Compare SOTAC with QUESTLAB in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SOTAC in NSE Scanner →